Loading...

Ariel Feldstein

TitleProfessor
InstitutionUniversity of California San Diego
DepartmentPediatrics
Address9500 Gilman Drive #0984
La Jolla CA 92093
Phone858-966-8907
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Gain of function mutations in inflammasome related genes in human and experimental alcoholic liver disease
    NIH/NIAAA U01AA024206Sep 20, 2017 - Aug 31, 2022
    Role: Principal Investigator
    Sterile inflammation and pyroptotic cell death in liver fibrosis
    NIH/NIDDK R01DK113592Mar 1, 2017 - Feb 28, 2022
    Role: Principal Investigator
    Encapsulated RNAs in extracellular vesicles contribute ALD progression
    NIH/NIAAA R21AA023574Sep 5, 2015 - Aug 31, 2017
    Role: Principal Investigator
    Oxidized Metabolites of Linoleic Acid in Alcohol-induced Liver Injury
    NIH/NIAAA U01AA022489Sep 1, 2014 - Jun 30, 2019
    Role: Principal Investigator
    Alcoholic liver disease: Biochemical, cellular and systemic responses to ethanol
    NIH P20AA017837Sep 30, 2009 - Aug 31, 2014
    Role: Co-Investigator
    Caspase Dependent Cell Death in Nonalcoholic Fatty Liver Disease
    NIH/NIDDK R01DK082451Aug 24, 2009 - Jun 30, 2013
    Role: Principal Investigator
    The Lysosomal-Mitochondrial Axis in Nonalcoholic Fatty Liver Disease
    NIH/NIDDK R01DK076852Mar 1, 2007 - Jan 31, 2013
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Inzaugarat ME, Johnson CD, Holtmann TM, McGeough MD, Trautwein C, Papouchado BG, Schwabe R, Hoffman HM, Wree A, Feldstein AE. NLRP3 inflammasome activation in hepatic stellate cells induces murine liver fibrosis. Hepatology. 2018 Sep 04. PMID: 30180270.
      View in: PubMed
    2. Mann J, Reeves HL, Feldstein AE. Liquid biopsy for liver diseases. Gut. 2018 Sep 03. PMID: 30177542.
      View in: PubMed
    3. Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein A. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One. 2018; 13(8):e0202226. PMID: 30161179.
      View in: PubMed
    4. Ramsden CE, Hennebelle M, Schuster S, Keyes GS, Johnson CD, Kirpich IA, Dahlen JE, Horowitz MS, Zamora D, Feldstein AE, McClain CJ, Muhlhausler BS, Makrides M, Gibson RA, Taha AY. Effects of diets enriched in linoleic acid and its peroxidation products on brain fatty acids, oxylipins, and aldehydes in mice. Biochim Biophys Acta. 2018 Jul 25; 1863(10):1206-1213. PMID: 30053599.
      View in: PubMed
    5. Schuster S, Johnson CD, Hennebelle M, Holtmann T, Taha AY, Kirpich IA, Eguchi A, Ramsden CE, Papouchado BG, McClain CJ, Feldstein AE. Oxidized linoleic acid metabolites induce liver mitochondrial dysfunction, apoptosis and NLRP3 activation in mice. J Lipid Res. 2018 Jul 03. PMID: 30084831.
      View in: PubMed
    6. Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018 May 08. PMID: 29740166.
      View in: PubMed
    7. Eguchi A, Koyama Y, Wree A, Johnson CD, Nakamura R, Povero D, Kneiber D, Tameda M, Contreras P, Spada A, Feldstein AE. Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation. J Mol Med (Berl). 2018 May 05. PMID: 29728708.
      View in: PubMed
    8. Kharbanda KK, Ronis MJJ, Shearn CT, Petersen DR, Zakhari S, Warner DR, Feldstein AE, McClain CJ, Kirpich IA. Role of Nutrition in Alcoholic Liver Disease: Summary of the Symposium at the ESBRA 2017 Congress. Biomolecules. 2018 Mar 26; 8(2). PMID: 29587455.
      View in: PubMed
    9. Wree A, Inzaugarat ME, Feldstein AE. Transmembrane BAX Inhibitor motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment. Hepatology. 2018 01; 67(1):438-441. PMID: 28859227.
      View in: PubMed
    10. McGeough MD, Wree A, Inzaugarat ME, Haimovich A, Johnson CD, Peña CA, Goldbach-Mansky R, Broderick L, Feldstein AE, Hoffman HM. TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J Clin Invest. 2017 Dec 01; 127(12):4488-4497. PMID: 29130929.
      View in: PubMed
    11. Warner DR, Liu H, Miller ME, Ramsden CE, Gao B, Feldstein AE, Schuster S, McClain CJ, Kirpich IA. Dietary Linoleic Acid and Its Oxidized Metabolites Exacerbate Liver Injury Caused by Ethanol via Induction of Hepatic Proinflammatory Response in Mice. Am J Pathol. 2017 Oct; 187(10):2232-2245. PMID: 28923202.
      View in: PubMed
    12. Wree A, McGeough MD, Inzaugarat ME, Eguchi A, Schuster S, Johnson CD, Peña CA, Geisler LJ, Papouchado BG, Hoffman HM, Feldstein AE. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice. Hepatology. 2017 Sep 13. PMID: 28902427.
      View in: PubMed
    13. Cabrera D, Wree A, Povero D, Solís N, Hernandez A, Pizarro M, Moshage H, Torres J, Feldstein AE, Cabello-Verrugio C, Brandan E, Barrera F, Arab JP, Arrese M. Andrographolide Ameliorates Inflammation and Fibrogenesis and Attenuates Inflammasome Activation in Experimental Non-Alcoholic Steatohepatitis. Sci Rep. 2017 Jun 14; 7(1):3491. PMID: 28615649.
      View in: PubMed
    14. Alegre F, Pelegrin P, Feldstein AE. Inflammasomes in Liver Fibrosis. Semin Liver Dis. 2017 May; 37(2):119-127. PMID: 28564720.
      View in: PubMed
    15. Tricò D, Di Sessa A, Caprio S, Chalasani N, Liu W, Liang T, Graf J, Herzog RI, Johnson CD, Umano GR, Feldstein AE, Santoro N. Oxidized Derivatives of Linoleic Acid in Pediatric Metabolic Syndrome: Is Their Pathogenic Role Modulated by the Genetic Background and the Gut Microbiota? Antioxid Redox Signal. 2017 Apr 07. PMID: 28279074.
      View in: PubMed
    16. Arrese M, Feldstein AE. NASH-RELATED CIRRHOSIS: AN OCCULT LIVER DISEASE BURDEN. Hepatol Commun. 2017 Apr; 1(2):84-86. PMID: 29335681.
      View in: PubMed
    17. Schuster S, Feldstein AE. NASH: Novel therapeutic strategies targeting ASK1 in NASH. Nat Rev Gastroenterol Hepatol. 2017 Jun; 14(6):329-330. PMID: 28377639.
      View in: PubMed
    18. Alkhouri N, Feldstein AE. Treating nonalcoholic steatohepatitis in children: Not a cinch task. Hepatology. 2017 04; 65(4):1407-1409. PMID: 28073147.
      View in: PubMed
    19. Cannito S, Morello E, Bocca C, Foglia B, Benetti E, Novo E, Chiazza F, Rogazzo M, Fantozzi R, Povero D, Sutti S, Bugianesi E, Feldstein AE, Albano E, Collino M, Parola M. Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. PLoS One. 2017; 12(3):e0172575. PMID: 28249038.
      View in: PubMed
    20. Mann JP, Feldstein AE, Nobili V. Update on lipid species and paediatric nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2017 Mar; 20(2):110-116. PMID: 27906700.
      View in: PubMed
    21. Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017 05; 66(5):1037-1046. PMID: 28167322.
      View in: PubMed
    22. Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE. Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. Hepatology. 2017 02; 65(2):475-490. PMID: 27639178.
      View in: PubMed
    23. Nobili V, Feldstein AE. Fatty liver in adolescents: Mechanisms, clinical features and therapy. J Hepatol. 2016 Dec; 65(6):1258-1260. PMID: 27742132.
      View in: PubMed
    24. Eguchi A, Lazic M, Armando AM, Phillips SA, Katebian R, Maraka S, Quehenberger O, Sears DD, Feldstein AE. Circulating adipocyte-derived extracellular vesicles are novel markers of metabolic stress. J Mol Med (Berl). 2016 11; 94(11):1241-1253. PMID: 27394413.
      View in: PubMed
    25. Inzaugarat ME, Wree A, Feldstein AE. Hepatocyte mitochondrial DNA released in microparticles and toll-like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis. Hepatology. 2016 08; 64(2):669-71. PMID: 27239763; PMCID: PMC4956555 [Available on 08/01/17].
    26. Smathers RL, Chiang DJ, McMullen MR, Feldstein AE, Roychowdhury S, Nagy LE. Soluble IgM links apoptosis to complement activation in early alcoholic liver disease in mice. Mol Immunol. 2016 Apr; 72:9-18. PMID: 26922040; PMCID: PMC4828291 [Available on 04/01/17].
    27. Wree A, Mehal WZ, Feldstein AE. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis. Semin Liver Dis. 2016 Feb; 36(1):27-36. PMID: 26870930; PMCID: PMC4955833.
    28. Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci. 2016 May; 61(5):1294-303. PMID: 26841783; PMCID: PMC4948286 [Available on 05/01/17].
    29. Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016 Aug; 65(8):1087-95. PMID: 26972222; PMCID: PMC4931968 [Available on 08/01/17].
    30. Povero D, Feldstein AE. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J. 2016 Feb; 40(1):1-11. PMID: 26912150; PMCID: PMC4768045.
    31. Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism. 2016 Aug; 65(8):1161-71. PMID: 26961580.
      View in: PubMed
    32. Goffredo M, Caprio S, Feldstein AE, D'Adamo E, Shaw MM, Pierpont B, Savoye M, Zhao H, Bale AE, Santoro N. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology. 2016 Jan; 63(1):117-25. PMID: 26457389; PMCID: PMC4688225 [Available on 01/01/17].
    33. Eguchi A, De Mollerat Du Jeu X, Johnson CD, Nektaria A, Feldstein AE. Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. J Hepatol. 2016 Mar; 64(3):699-707. PMID: 26555271.
      View in: PubMed
    34. Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, Pinatel EM, Alisi A, Nobili V, Feldstein AE. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-?. Cell Mol Gastroenterol Hepatol. 2015 Nov 01; 1(6):646-663.e4. PMID: 26783552.
      View in: PubMed
    35. Kathemann S, Bechmann LP, Sowa JP, Manka P, Dechêne A, Gerner P, Lainka E, Hoyer PF, Feldstein AE, Canbay A. Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center. Ann Hepatol. 2015 Sep-Oct; 14(5):722-8. PMID: 26256901.
      View in: PubMed
    36. Pan JJ, Fisher-Hoch SP, Chen C, Feldstein AE, McCormick JB, Rahbar MH, Beretta L, Fallon MB. Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort. World J Hepatol. 2015 Jun 18; 7(11):1586-94. PMID: 26085918; PMCID: PMC4462697.
    37. Eguchi A, Yoshitomi T, Lazic M, Johnson CD, Vong LB, Wree A, Povero D, Papouchado BG, Nagasaki Y, Feldstein AE. Redox nanoparticles as a novel treatment approach for inflammation and fibrosis associated with nonalcoholic steatohepatitis. Nanomedicine (Lond). 2015; 10(17):2697-708. PMID: 26020857; PMCID: PMC4910954.
    38. Nagpal SJ, Lopez R, Feldstein AE, Alkhouri N. Serum cytokeratin-18 fragment levels predict development of type 2 diabetes mellitus in adult patients with NAFLD. Liver Int. 2015 Dec; 35(12):2621. PMID: 25939859.
      View in: PubMed
    39. Eguchi A, Mulya A, Lazic M, Radhakrishnan D, Berk MP, Povero D, Gornicka A, Feldstein AE. Microparticles release by adipocytes act as "find-me" signals to promote macrophage migration. PLoS One. 2015; 10(4):e0123110. PMID: 25849214; PMCID: PMC4388837.
    40. Alkhouri N, Alisi A, Okwu V, Matloob A, Ferrari F, Crudele A, De Vito R, Lopez R, Feldstein AE, Nobili V. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015 Aug; 60(8):2353-9. PMID: 25764498.
      View in: PubMed
    41. Pizarro M, Solís N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int. 2015 Sep; 35(9):2129-38. PMID: 25646700; PMCID: PMC4522413.
    42. Dechêne A, Kodde C, Kathemann S, Treckmann J, Lainka E, Paul A, Gerken G, Feldstein AE, Hoyer PF, Canbay A. Endoscopic treatment of pediatric post-transplant biliary complications is safe and effective. Dig Endosc. 2015 May; 27(4):505-11. PMID: 25545826.
      View in: PubMed
    43. Arrese M, Eguchi A, Feldstein AE. Circulating microRNAs: emerging biomarkers of liver disease. Semin Liver Dis. 2015 Feb; 35(1):43-54. PMID: 25632934.
      View in: PubMed
    44. Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci. 2015 May; 60(5):1440-7. PMID: 25540086.
      View in: PubMed
    45. Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One. 2014; 9(12):e113651. PMID: 25470250; PMCID: PMC4254757.
    46. Liu H, Beier JI, Arteel GE, Ramsden CE, Feldstein AE, McClain CJ, Kirpich IA. Transient receptor potential vanilloid 1 gene deficiency ameliorates hepatic injury in a mouse model of chronic binge alcohol-induced alcoholic liver disease. Am J Pathol. 2015 Jan; 185(1):43-54. PMID: 25447051; PMCID: PMC4278357.
    47. Lazic M, Inzaugarat ME, Povero D, Zhao IC, Chen M, Nalbandian M, Miller YI, Cherñavsky AC, Feldstein AE, Sears DD. Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis. PLoS One. 2014; 9(9):e107658. PMID: 25251155; PMCID: PMC4175074.
    48. Navarro LA, Wree A, Povero D, Berk MP, Eguchi A, Ghosh S, Papouchado BG, Erzurum SC, Feldstein AE. Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis. J Hepatol. 2015 Feb; 62(2):412-20. PMID: 25234945.
      View in: PubMed
    49. Wree A, Schlattjan M, Bechmann LP, Claudel T, Sowa JP, Stojakovic T, Scharnagl H, Köfeler H, Baba HA, Gerken G, Feldstein AE, Trauner M, Canbay A. Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. Metabolism. 2014 Dec; 63(12):1542-52. PMID: 25267016.
      View in: PubMed
    50. Eguchi A, Feldstein AE. Adipocyte cell death, fatty liver disease and associated metabolic disorders. Dig Dis. 2014; 32(5):579-85. PMID: 25034291; PMCID: PMC4512744.
    51. Wree A, McGeough MD, Peña CA, Schlattjan M, Li H, Inzaugarat ME, Messer K, Canbay A, Hoffman HM, Feldstein AE. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med (Berl). 2014 Oct; 92(10):1069-82. PMID: 24861026; PMCID: PMC4349416.
    52. Thapaliya S, Wree A, Povero D, Inzaugarat ME, Berk M, Dixon L, Papouchado BG, Feldstein AE. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig Dis Sci. 2014 Jun; 59(6):1197-206. PMID: 24795036; PMCID: PMC4512760.
    53. Aytekin M, Tonelli AR, Farver CF, Feldstein AE, Dweik RA. Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice. Int J Clin Exp Pathol. 2014; 7(5):1935-46. PMID: 24966903; PMCID: PMC4069962.
    54. Navaneethan U, Gutierrez NG, Venkatesh PG, Jegadeesan R, Zhang R, Jang S, Sanaka MR, Vargo JJ, Parsi MA, Feldstein AE, Stevens T. Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study. Am J Gastroenterol. 2014 Jun; 109(6):895-902. PMID: 24710507.
      View in: PubMed
    55. Lazic M, Eguchi A, Berk MP, Povero D, Papouchado B, Mulya A, Johnson CD, Feldstein AE. Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice. J Hepatol. 2014 Jul; 61(1):107-15. PMID: 24681344.
      View in: PubMed
    56. Feldstein AE, Patton-Ku D, Boutelle KN. Obesity, nutrition, and liver disease in children. Clin Liver Dis. 2014 Feb; 18(1):219-31. PMID: 24274876; PMCID: PMC4008146.
    57. Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2014 Mar; 59(3):898-910. PMID: 23813842; PMCID: PMC4008151.
    58. Alkhouri N, Berk M, Yerian L, Lopez R, Chung YM, Zhang R, McIntyre TM, Feldstein AE, Hazen SL. OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease. Dig Dis Sci. 2014 Jul; 59(7):1617-24. PMID: 24464211; PMCID: PMC4279921.
    59. Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014 May; 60(5):1063-74. PMID: 24412608.
      View in: PubMed
    60. Masuda T, Fu Y, Eguchi A, Czogalla J, Rose MA, Kuczkowski A, Gerasimova M, Feldstein AE, Scadeng M, Vallon V. Dipeptidyl peptidase IV inhibitor lowers PPAR? agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention. Am J Physiol Endocrinol Metab. 2014 Feb 15; 306(4):E388-98. PMID: 24347054; PMCID: PMC3923087.
    61. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract. 2013; 2013:498296. PMID: 24348536; PMCID: PMC3855930.
    62. Povero D, Eguchi A, Niesman IR, Andronikou N, de Mollerat du Jeu X, Mulya A, Berk M, Lazic M, Thapaliya S, Parola M, Patel HH, Feldstein AE. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require Vanin-1 for uptake by endothelial cells. Sci Signal. 2013 Oct 08; 6(296):ra88. PMID: 24106341; PMCID: PMC4016801.
    63. Gulati R, Radhakrishnan KR, Hupertz V, Wyllie R, Alkhouri N, Worley S, Feldstein AE. Health-related quality of life in children with autoimmune liver disease. J Pediatr Gastroenterol Nutr. 2013 Oct; 57(4):444-50. PMID: 23783017.
      View in: PubMed
    64. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013 Nov; 10(11):627-36. PMID: 23958599.
      View in: PubMed
    65. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014 Jan; 60(1):167-74. PMID: 23973932.
      View in: PubMed
    66. Santoro N, Caprio S, Giannini C, Kim G, Kursawe R, Pierpont B, Shaw MM, Feldstein AE. Oxidized fatty acids: A potential pathogenic link between fatty liver and type 2 diabetes in obese adolescents? Antioxid Redox Signal. 2014 Jan 10; 20(2):383-9. PMID: 23815500; PMCID: PMC3887421.
    67. Santoro N, Caprio S, Feldstein AE. Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis. Clin Lipidol. 2013 Aug 01; 8(4):411-418. PMID: 26405460.
      View in: PubMed
    68. Bansal S, Berk M, Alkhouri N, Partrick DA, Fung JJ, Feldstein A. Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. J Surg Res. 2014 Jan; 186(1):29-38. PMID: 24135379; PMCID: PMC3923502.
    69. Ramsden CE, Faurot KR, Zamora D, Suchindran CM, Macintosh BA, Gaylord S, Ringel A, Hibbeln JR, Feldstein AE, Mori TA, Barden A, Lynch C, Coble R, Mas E, Palsson O, Barrow DA, Mann JD. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain. 2013 Nov; 154(11):2441-51. PMID: 23886520.
      View in: PubMed
    70. Puri K, Nobili V, Melville K, Corte CD, Sartorelli MR, Lopez R, Feldstein AE, Alkhouri N. Serum bilirubin level is inversely associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2013 Jul; 57(1):114-8. PMID: 23518490.
      View in: PubMed
    71. Hillian AD, McMullen MR, Sebastian BM, Roychowdhury S, Rowchowdhury S, Kashyap SR, Schauer PR, Kirwan JP, Feldstein AE, Nagy LE. Mice lacking C1q are protected from high fat diet-induced hepatic insulin resistance and impaired glucose homeostasis. J Biol Chem. 2013 Aug 02; 288(31):22565-75. PMID: 23788643; PMCID: PMC3829343.
    72. Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol. 2013 Sep; 108(9):1526-31. PMID: 23752877.
      View in: PubMed
    73. Giannini C, Feldstein AE, Santoro N, Kim G, Kursawe R, Pierpont B, Caprio S. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab. 2013 Jul; 98(7):2993-3000. PMID: 23626003; PMCID: PMC3701279.
    74. Eguchi A, Povero D, Alkhouri N, Feldstein AE. Novel therapeutic targets for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2013 Jul; 17(7):773-9. PMID: 23600493.
      View in: PubMed
    75. Eguchi A, Feldstein AE. Lysosomal Cathepsin D contributes to cell death during adipocyte hypertrophy. Adipocyte. 2013 Jul 01; 2(3):170-5. PMID: 23991364; PMCID: PMC3756106.
    76. Dixon LJ, Flask CA, Papouchado BG, Feldstein AE, Nagy LE. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS One. 2013; 8(2):e56100. PMID: 23409132; PMCID: PMC3567081.
    77. Santoro N, Feldstein AE, Enoksson E, Pierpont B, Kursawe R, Kim G, Caprio S. The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants. Diabetes Care. 2013 May; 36(5):1353-60. PMID: 23275357; PMCID: PMC3631865.
    78. Alkhouri N, Sedki E, Alisi A, Lopez R, Pinzani M, Feldstein AE, Nobili V. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int. 2013 Jan; 33(1):79-85. PMID: 23146095.
      View in: PubMed
    79. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, Hazen SL, Feldstein AE. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 2012 Oct; 56(4):1291-9. PMID: 22505276; PMCID: PMC3430813.
    80. Ramsden CE, Ringel A, Feldstein AE, Taha AY, MacIntosh BA, Hibbeln JR, Majchrzak-Hong SF, Faurot KR, Rapoport SI, Cheon Y, Chung YM, Berk M, Mann JD. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot Essent Fatty Acids. 2012 Oct-Nov; 87(4-5):135-41. PMID: 22959954.
      View in: PubMed
    81. Kim G, Giannini C, Pierpont B, Feldstein AE, Santoro N, Kursawe R, Shaw M, Duran E, Goldberg R, Dziura J, Caprio S. Longitudinal effects of MRI-measured hepatic steatosis on biomarkers of glucose homeostasis and hepatic apoptosis in obese youth. Diabetes Care. 2013 Jan; 36(1):130-6. PMID: 22933439; PMCID: PMC3526202.
    82. Alkhouri N, De Vito R, Alisi A, Yerian L, Lopez R, Feldstein AE, Nobili V. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol. 2012 Dec; 57(6):1312-8. PMID: 22871498.
      View in: PubMed
    83. Gornicka A, Fettig J, Eguchi A, Berk MP, Thapaliya S, Dixon LJ, Feldstein AE. Adipocyte hypertrophy is associated with lysosomal permeability both in vivo and in vitro: role in adipose tissue inflammation. Am J Physiol Endocrinol Metab. 2012 Sep 01; 303(5):E597-606. PMID: 22739104; PMCID: PMC3468510.
    84. Stevens T, Berk MP, Lopez R, Chung YM, Zhang R, Parsi MA, Bronner MP, Feldstein AE. Lipidomic profiling of serum and pancreatic fluid in chronic pancreatitis. Pancreas. 2012 May; 41(4):518-22. PMID: 22504378.
      View in: PubMed
    85. De Vito R, Alisi A, Masotti A, Ceccarelli S, Panera N, Citti A, Salata M, Valenti L, Feldstein AE, Nobili V. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int J Mol Med. 2012 Jul; 30(1):49-56. PMID: 22505182.
      View in: PubMed
    86. Tonelli AR, Aytekin M, Feldstein AE, Dweik RA. Leptin levels predict survival in pulmonary arterial hypertension. Pulm Circ. 2012 Apr-Jun; 2(2):214-9. PMID: 22837862; PMCID: PMC3401875.
    87. Alkhouri N, Feldstein AE. The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology. 2012 Apr; 55(4):1292-5. PMID: 22461076; PMCID: PMC3325147.
    88. Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012 May; 92(5):713-23. PMID: 22411067; PMCID: PMC3808241.
    89. Roychowdhury S, Chiang DJ, Mandal P, McMullen MR, Liu X, Cohen JI, Pollard J, Feldstein AE, Nagy LE. Inhibition of apoptosis protects mice from ethanol-mediated acceleration of early markers of CCl4 -induced fibrosis but not steatosis or inflammation. Alcohol Clin Exp Res. 2012 Jul; 36(7):1139-47. PMID: 22273278; PMCID: PMC3337974.
    90. Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol. 2012 Jan 17; 9(3):152-61. PMID: 22249728.
      View in: PubMed
    91. Alkhouri N, Kistangari G, Campbell C, Lopez R, Zein NN, Feldstein AE. Mean platelet volume as a marker of increased cardiovascular risk in patients with nonalcoholic steatohepatitis. Hepatology. 2012 Jan; 55(1):331. PMID: 21969091; PMCID: PMC3245344.
    92. Moses J, Alkhouri N, Shannon A, Feldstein A, Carter-Kent C. Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab. Inflamm Bowel Dis. 2011 Dec; 17(12):E160. PMID: 21953938.
      View in: PubMed
    93. Alkhouri N, Morris-Stiff G, Campbell C, Lopez R, Tamimi TA, Yerian L, Zein NN, Feldstein AE. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2012 Feb; 32(2):297-302. PMID: 22097893.
      View in: PubMed
    94. Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol. 2012 Jan; 107(1):133-8. PMID: 21876562.
      View in: PubMed
    95. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011 Nov; 54(5):1610-9. PMID: 21748765; PMCID: PMC3205292.
    96. Sebastian BM, Roychowdhury S, Tang H, Hillian AD, Feldstein AE, Stahl GL, Takahashi K, Nagy LE. Identification of a cytochrome P4502E1/Bid/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice. J Biol Chem. 2011 Oct 14; 286(41):35989-97. PMID: 21856753; PMCID: PMC3195631.
    97. Nobili V, Della Corte C, Monti L, Alisi A, Feldstein A. The use of ultrasound in clinical setting for children affected by NAFLD: is it safe and accurate? Ital J Pediatr. 2011 Aug 02; 37:36. PMID: 21810223; PMCID: PMC3161934.
    98. Shannon A, Alkhouri N, Carter-Kent C, Monti L, Devito R, Lopez R, Feldstein AE, Nobili V. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. J Pediatr Gastroenterol Nutr. 2011 Aug; 53(2):190-5. PMID: 21788761; PMCID: PMC3144505.
    99. Nobili V, Carter-Kent C, Feldstein AE. The role of lifestyle changes in the management of chronic liver disease. BMC Med. 2011 Jun 06; 9:70. PMID: 21645344; PMCID: PMC3127780.
    100. Alkhouri N, Carter-Kent C, Elias M, Feldstein AE. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol. 2011 Jun 01; 6(3):305-314. PMID: 22162978.
      View in: PubMed
    101. Feldstein AE, Bailey SM. Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease. Antioxid Redox Signal. 2011 Jul 15; 15(2):421-4. PMID: 21254858; PMCID: PMC3118602.
    102. Kohli R, Feldstein AE. NASH animal models: are we there yet? J Hepatol. 2011 Oct; 55(4):941-3. PMID: 21708199.
      View in: PubMed
    103. Gornicka A, Morris-Stiff G, Thapaliya S, Papouchado BG, Berk M, Feldstein AE. Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid Redox Signal. 2011 Jul 15; 15(2):437-45. PMID: 21194384; PMCID: PMC3118609.
    104. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011 Apr 07; 472(7341):57-63. PMID: 21475195; PMCID: PMC3086762.
    105. Alkhouri N, Carter-Kent C, Feldstein AE. Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol. 2011 Apr; 5(2):201-12. PMID: 21476915; PMCID: PMC3119461.
    106. Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, Schauer PR, Zein NN, Feldstein AE. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011 Jun; 54(6):1224-9. PMID: 21145805; PMCID: PMC3098936.
    107. Carter-Kent C, Brunt EM, Yerian LM, Alkhouri N, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2011 Feb; 52(2):190-7. PMID: 21240012.
      View in: PubMed
    108. Adams LA, Feldstein AE. Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. J Dig Dis. 2011 Feb; 12(1):10-6. PMID: 21091933.
      View in: PubMed
    109. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis. 2010 Nov; 30(4):391-401. PMID: 20960378.
      View in: PubMed
    110. Feldstein AE, Nobili V. Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children. J Pediatr Gastroenterol Nutr. 2010 Oct; 51(4):378-9. PMID: 20808243; PMCID: PMC2950320.
    111. Alkhouri N, Carter-Kent C, Lopez R, Rosenberg WM, Pinzani M, Bedogni G, Feldstein AE, Nobili V. A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. Clin Gastroenterol Hepatol. 2011 Feb; 9(2):150-5. PMID: 20888433.
      View in: PubMed
    112. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010 Oct; 4(5):623-35. PMID: 20932147.
      View in: PubMed
    113. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010 Sep; 52(3):934-44. PMID: 20607689; PMCID: PMC2932817.
    114. Morris-Stiff G, Feldstein AE. Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. J Hepatol. 2010 Nov; 53(5):795-6. PMID: 20800308.
      View in: PubMed
    115. Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res. 2010 Oct; 51(10):3046-54. PMID: 20631297; PMCID: PMC2936759.
    116. Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, Feldstein AE. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res. 2010 Jun; 67(6):665-70. PMID: 20496475.
      View in: PubMed
    117. Yang L, Latchoumycandane C, McMullen MR, Pratt BT, Zhang R, Papouchado BG, Nagy LE, Feldstein AE, McIntyre TM. Chronic alcohol exposure increases circulating bioactive oxidized phospholipids. J Biol Chem. 2010 Jul 16; 285(29):22211-20. PMID: 20460374; PMCID: PMC2903350.
    118. Radhakrishnan KR, Alkhouri N, Worley S, Arrigain S, Hupertz V, Kay M, Yerian L, Wyllie R, Feldstein AE. Autoimmune hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis. 2010 Oct; 42(10):724-8. PMID: 20163994.
      View in: PubMed
    119. Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci. 2010 Sep; 55(9):2644-50. PMID: 19960252.
      View in: PubMed
    120. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci. 2009 Dec; 54(12):2699-705. PMID: 19148751.
      View in: PubMed
    121. Alkhouri N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, Kashyap S, Schauer PR, Feldstein AE. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem. 2010 Jan 29; 285(5):3428-38. PMID: 19940134; PMCID: PMC2823448.
    122. Alkhouri N, Lopez R, Berk M, Feldstein AE. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol. 2009 Nov-Dec; 43(10):985-9. PMID: 19525859; PMCID: PMC2783954.
    123. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009 Oct; 50(4):1072-8. PMID: 19585618; PMCID: PMC2757511.
    124. Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, Xanthakos SA, Whitington PF, Charatcharoenwitthaya P, Yap J, Lopez R, McCullough AJ, Feldstein AE. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology. 2009 Oct; 50(4):1113-20. PMID: 19637190; PMCID: PMC2775705.
    125. Chen R, Feldstein AE, McIntyre TM. Suppression of mitochondrial function by oxidatively truncated phospholipids is reversible, aided by bid, and suppressed by Bcl-XL. J Biol Chem. 2009 Sep 25; 284(39):26297-308. PMID: 19654426; PMCID: PMC2785317.
    126. Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol. 2009 Aug; 3(4):445-51. PMID: 19673631; PMCID: PMC2775708.
    127. Carter-Kent C, Feldstein AE. Non-alcoholic steatohepatitis over multiple generations. Dig Dis Sci. 2010 May; 55(5):1494-7. PMID: 19629685.
      View in: PubMed
    128. Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL, Stein CM. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring). 2009 Sep; 17(9):1696-701. PMID: 19360015; PMCID: PMC2829436.
    129. Feldstein A, Kleiner D, Kravetz D, Buck M. Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor. J Clin Gastroenterol. 2009 Apr; 43(4):374-81. PMID: 19098685.
      View in: PubMed
    130. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Role of interleukin-6 in human nonalcoholic steatohepatitis. Response to Dogru et al. Am J Gastroenterol. 2009 Mar; 104(3):author reply 788. PMID: 19174778.
      View in: PubMed
    131. Nobili V, Alkhouri N, Alisi A, Ottino S, Lopez R, Manco M, Feldstein AE. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 May; 7(5):575-9. PMID: 19268270.
      View in: PubMed
    132. Li ZZ, Berk M, McIntyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem. 2009 Feb 27; 284(9):5637-44. PMID: 19119140; PMCID: PMC2645822.
    133. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008 Nov; 28(4):386-95. PMID: 18956295.
      View in: PubMed
    134. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008 Sep; 14(9):1287-93. PMID: 18756451.
      View in: PubMed
    135. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, Hazen SL, Feldstein AE. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol. 2008 Nov; 6(11):1249-54. PMID: 18995215; PMCID: PMC2628560.
    136. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008 Jun; 103(6):1372-9. PMID: 18510618.
      View in: PubMed
    137. Hanouneh IA, Feldstein AE, Lopez R, Yerian L, Pillai A, Zein CO, Zein NN. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008 May; 6(5):584-9. PMID: 18455698.
      View in: PubMed
    138. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology. 2008 May; 47(5):1495-503. PMID: 18220271; PMCID: PMC3025414.
    139. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008 Apr; 103(4):1036-42. PMID: 18177455.
      View in: PubMed
    140. Carter-Kent C, Radhakrishnan K, Feldstein AE. Increasing calories, decreasing morbidity and mortality: is improved nutrition the answer to better outcomes in patients with biliary atresia? Hepatology. 2007 Nov; 46(5):1329-31. PMID: 17969044.
      View in: PubMed
    141. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007 Aug; 46(2):582-9. PMID: 17661414.
      View in: PubMed
    142. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006 Jul; 44(1):27-33. PMID: 16799979.
      View in: PubMed
    143. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am J Physiol Gastrointest Liver Physiol. 2006 Jun; 290(6):G1339-46. PMID: 16484678; PMCID: PMC3056273.
    144. Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005 Oct; 17(5):636-41. PMID: 16160540.
      View in: PubMed
    145. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci. 2005 Sep 01; 10:3093-9. PMID: 15970563.
      View in: PubMed
    146. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul; 129(1):113-21. PMID: 16012941.
      View in: PubMed
    147. Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2005 Apr; 3(4):384-9. PMID: 15822044.
      View in: PubMed
    148. Feldstein AE, Gores GJ. An apoptosis biomarker goes to the HCV clinic. Hepatology. 2004 Nov; 40(5):1044-6. PMID: 15486920.
      View in: PubMed
    149. Feldstein A, Gores GJ. Steatohepatitis and apoptosis: therapeutic implications. Am J Gastroenterol. 2004 Sep; 99(9):1718-9. PMID: 15330908.
      View in: PubMed
    150. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004 Jul; 40(1):185-94. PMID: 15239102.
      View in: PubMed
    151. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology. 2004 Apr; 39(4):909-14. PMID: 15057893.
      View in: PubMed
    152. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol. 2003 Dec; 39(6):978-83. PMID: 14642615.
      View in: PubMed
    153. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther. 2004 Mar; 308(3):1191-6. PMID: 14617689.
      View in: PubMed
    154. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, Gores GJ. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003 Nov; 38(5):1188-98. PMID: 14578857.
      View in: PubMed
    155. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003 Aug; 125(2):437-43. PMID: 12891546.
      View in: PubMed
    156. Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, Taniai M, Gores GJ. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest. 2003 Jul; 112(2):152-9. PMID: 12865404; PMCID: PMC164289.
    157. Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003 Jul; 38(1):210-7. PMID: 12830004.
      View in: PubMed
    158. Wilson SH, Chade AR, Feldstein A, Sawamura T, Napoli C, Lerman A, Lerman LO. Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. Nephrol Dial Transplant. 2003 Apr; 18(4):703-9. PMID: 12637638.
      View in: PubMed
    159. Feldstein AE, Razonable RR, Boyce TG, Freese DK, El-Youssef M, Perrault J, Paya CV, Ishitani MB. Prevalence and clinical significance of human herpesviruses 6 and 7 active infection in pediatric liver transplant patients. Pediatr Transplant. 2003 Apr; 7(2):125-9. PMID: 12654053.
      View in: PubMed
    160. Feldstein AE, Miller SM, El-Youssef M, Rodeberg D, Lindor NM, Burgart LJ, Szurszewski JH, Farrugia G. Chronic intestinal pseudoobstruction associated with altered interstitial cells of cajal networks. J Pediatr Gastroenterol Nutr. 2003 Apr; 36(4):492-7. PMID: 12658043.
      View in: PubMed
    Ariel's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _